Effect of Sacubitril Valsartan Sodium Tablets Combined with Metoprolol in the Treatment of Elderly Patients with Coronary Heart Disease Complicated with Heart Failure
Objective:To investigate the clinical efficacy of sacubitril valsartan sodium tablets combined with metoprolol in the treatment of elderly patients with coronary heart disease and heart failure.Methods:From January 2021 to January 2023,100 elderly patients with coronary heart disease and heart failure admitted to Weishi County Hospital of Traditional Chinese Medicine in Kaifeng City,Henan Province were selected for study.The patients were divided into two groups by alternating grouping method.The conventional group(50 patients)was treated with metoprolol orally,and the study group(50 patients)was treated with sacubitril valsartan sodium tablets combined with metoprolol orally.The therapeutic effect,cardiac function[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)],myocardial enzyme spectrum levels[creatine kinase(CK),creatine kinase isoenzyme(CK-MB),lactate dehydrogenase(LDH)]and creatinine(Scr),urea nitrogen(BUN),B-type natriuretic peptide(BNP)levels were compared between the two groups,and the incidence of adverse reactions was compared between the two groups.Results:The clinical effective rate of the study group was higher than that of the conventional group(P<0.05).The level of LVEF in the study group was higher,and the levels of LVEDD,LVESD,CK,CK-MB,LDH and BNP were lower than those in the conventional group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Sacubactril valsartan sodium tablets combined with metoprolol can effectively improve the clinical efficacy of patients with coronary heart disease complicated with heart failure,improve the heart function,reduce the burden of kidney,and have higher safety.
NETL
NSTL
万方数据
